“But we didn’t know the exact role they play, or how they work to drive lung cancer progression. I think this study really ...

He added, "But we didn't know the exact role they play, or how they work to drive lung cancer progression. I think this study ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

Prospects for the drug had already suffered a blow in 2022, when it did not slow disease progression when tested on a ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 ...

Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer ...

Roche is to end a novel lung cancer treatment trial, the Swiss company confirmed on Thursday, following "disappointing" ...

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared ...

A tracer known as FAPI performed better than the commonly used 18F-FDG for capturing early signs of pulmonary fibrosis on PET ...

In 5-year follow-up data from the phase III CROWN trial of ALK -positive advanced non-small cell lung cancer (NSCLC), ...

What is the life expectancy of someone with interstitial lung disease? Answered by Dr. Howard E. Lewine M.D. Chief Medical ...

A flawed new algorithm for distributing lungs to transplant patients wound up putting people with Type O blood at a ...